BMS-986189

• Description :

  BMS-986189 is a macrocyclic peptide PD-1/PD-L1 interaction with an IC50 of 1.03 nM inhibitor. BMS-986189 can be used for cancer research, such as human lung carcinoma cells L2987[1][2].

• UNSPSC :

  12352209

• Target :

  PD-1/PD-L1

• Type :

  Peptides

• Related Pathways :

  Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cancer; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/bms-986189.html

• Purity :

  99.58

• Solubility :

  DMSO : ≥ 100 mg/mL|H2O : ≥ 1 mg/mL

• Smiles :

  OC(CN1C2=CC=CC=C2C(C[C@H]3C(N([C@H](C(N([C@H](C(N[C@H](C(N[C@@H](CSCC(N[C@H](C(N([C@H](C(N[C@H](C(N4[C@](CCC4)([H])C(N[C@H](C(N[C@H](C(N5[C@](C[C@H](C5)O)([H])C(N[C@H](C(N[C@H](C(N3)=O)CCN)=O)CC6=CNC7=CC=CC=C67)=O)=O)CC(C)C)=O)CN)=O)=O)CC(N)=O)=O)C)C)=O)CC8=CC=C(C=C8)O)=O)C(NCC(N)=O)=O)=O)CC(C)C)=O)CCCC)C)=O)CCCC)C)=O)=C1)=O

• Molecular Formula :

  C91H131N21O21S

• Molecular Weight :

  1887.21

• References & Citations :

  [1]Yang J, et al. Utilization of macrocyclic peptides to target protein-protein interactions in cancer. Front Oncol. 2022 Nov 17;12:992171.|[2]Donnelly DJ, et al. The discovery and evaluation of [18F]BMS-986229, a novel macrocyclic peptide PET radioligand for the measurement of PD-L1 expression and in-vivo PD-L1 target engagement. Eur J Nucl Med Mol Imaging. 2024 Mar;51 (4) :978-990.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Scientific Category :

  Peptides

• Clinical Information :

  Phase 1

• CAS Number :

  [1629665-96-8]